CEPI

21 May

The next pandemic could begin anywhere, at any moment. And the risk of a deadly outbreak is only rising. But it doesn’t have to be that way. CEPI 3.0 is our plan to move the world from reactive response to proactive protection.

cepi.netFirst participants vaccinated with Oxford's CEPI-backed Lassa shot in GhanaThe study will provide additional data on the investigational shot, ChAdOx1 LassaJ.

A landmark new CEPI-funded trial has launched in Ghana assessing the @ox.ac.uk’s promising vaccine candidate against Lassa fever, the deadly disease which affects hundreds of thousands across West Africa each year. cepi.net/first-partic...

Final preparations are underway for Tumaini, which means “hope” in Swahili. This pivotal Phase 2/3 clinical trial will evaluate the safety, immunogenicity and efficacy of vaccine candidates against Bundibugyo virus, including Ervebo which is currently licensed for use to prevent Ebola virus.

cepi.netFinal preparations underway for pivotal Phase 2/3 Bundibugyo vaccine trialTumaini, a pivotal Phase 2/3 clinical trial, will evaluate vaccine candidates including Ervebo as part of the DRC's outbreak response.

The trial will support the Government-led response to the ongoing outbreak in the Democratic Republic of the Congo (DRC). Subject to ethical and regulatory approval, it is expected to begin in the coming weeks. Read more about the trial here: cepi.net/final-prepar...

Pandemics are one of 17 catastrophic global threats to health and human survival this century, alongside nuclear conflict, climate change and obesity. But their impact can be reduced through collective action and investment in preparedness. (1/2)

thelancet.comThe Lancet Commission on 21st century global threats to healthThe Lancet Commission on 21st Century Global Threats to Health is an independent, foresight-driven initiative that applies quantitative and qualitative methods to identify, characterise, and prioritis...

That’s the finding of the new Lancet Commission on 21st Century Global Threats to Health, published yesterday. ➡️ Read the Commission’s report: www.thelancet.com/commissions-... (2/2)

lshtm.ac.ukUganda launches Phase I clinical study of Bundibugyo virus disease vaccineUganda launches Phase I clinical study of Bundibugyo virus disease vaccine | LSHTM

A new early-stage trial assessing @ox.ac.uk's Bundibugyo ebolavirus vaccine candidate has launched in Uganda. The CEPI-funded study is being conducted by MRC/UVRI & LSHTM Uganda Research Unit with @ovg.ox.ac.uk and Pandemic Sciences Institute and the Serum Institute of India manufacturing doses.

linkedin.comPartners back CEPI's global pandemic preparedness plan with US$240 millionRecent outbreaks, like the deadly Bundibugyo ebolavirus, are a reminder of how quickly dangerous pathogens can emerge and spread, but they also hint at what is possible when the right capabilities, pa...

CEPI's September newsletter is now available! 🗞️ This month spotlights continued momentum for CEPI 3.0, with $240 million in new funding pledged by partners at UNGA 81. It also features our latest R&D partnerships, new funding opportunities and lots more.

As global health leaders ready themselves for this year’s World Health Summit Health Summit in Berlin, CEPI invites you to join its official panel discussion, From Crisis Response to Resilience: Innovating for Health Security Beyond Borders. Register: www.worldhealthsummit.org/sessions/034...

New funding: The @bioprevail.bsky.social x CEPI Biosecurity Innovation Challenge is seeking practical biosafety and biosecurity innovations to strengthen vaccine R&D and manufacturing during epidemic and pandemic responses, supporting CEPI’s 100 Days Mission: bioprevail.org/challenge/bi...

Three teams will receive a six-month accelerator, including up to US$50,000 in funding each, technical mentorship and access to global health experts, culminating in a showcase in Geneva in May 2027. Deadline: 31 October 2026, 11:59 p.m. CET.

21 Sept

🔉 Major new funding for CEPI announced today. Ethiopia, Norway and the UK have pledged a combined US$240 million to support CEPI’s five-year plan to transform the world’s ability to prevent and respond to future epidemic and pandemic threats. cepi.net/ethiopia-nor...

As CEPI CEO Dr Hatchett said: “By backing CEPI 3.0, Ethiopia, Norway and the UK are showing the kind of foresight and leadership that global health security depends on. Their investments will strengthen the world's disease defences, helping us respond rapidly and equitably to emerging viral threats”

21 Sept

Thank you to Ethiopia, Norway and the UK for backing CEPI 3.0. Read the full announcement to learn more: cepi.net/ethiopia-nor....

The commitments, announced during CEPI’s side event at the 81st session of the UN General Assembly, will support CEPI 3.0, the Coalition's 2027–2031 strategy to systematically reduce the likelihood, impact and cost of epidemics and pandemics.

cepi.netNew research set to strengthen epidemic intelligence and modelling for Bundibugyo virus responseCEPI is investing US$3.9 million in three research projects that will turn real-time outbreak data into actionable insights to guide the Bundibugyo ebolavirus response in the DRC and support vaccine t...

17 Sept

Good decisions in an outbreak depend on good evidence. That’s why CEPI is investing US$3.9 million in three research projects to strengthen understanding of the Bundibugyo ebolavirus (BDBV) outbreak in the DRC, helping guide the response and support clinical trials of BDBV vaccine candidates ⬇️

CEPI reposted

Pandemic Center at Brown University’s School of Public Health

@pandemiccenter.bsky.social

11 Sept

We’re thrilled to announce our new cohort of Fellows! Supported by @carnegie.org, this program builds biosecurity expertise by placing Fellows with leading global organizations to reduce biothreats. Read our full release ⤵️ pandemics.sph.brown.edu/news/2026-09...

pandemics.sph.brown.eduBacked by an Award from the Andrew Carnegie Foundation, the Brown Pandemic Center Launches a New Fellowship to Advance Global Biothreat Reduction, New Cohort Announced

cepi.netIndia ramps up Disease X preparedness with $8.9 million funding boost for its freezer-free RNA vaccineThe funding will advance clinical testing of Immunoscript's thermostable next-generation RNA vaccine platform.

9 Sept

Today we announced new funding of up to US$8.9 million in Immunoscript Life Science to advance clinical testing of its thermostable next-generation self-amplifying RNA vaccine technology 🔽

cepi.netIndonesia steps up Southeast Asia’s outbreak preparedness with pandemic simulation exerciseOver 120 experts working across the vaccine and epidemic preparedness research ecosystem in Indonesia and the region are taking part in the table-top event in Jakarta.

4 Sept

This week we hosted a landmark pandemic simulation exercise with Indonesia's Ministry of Health to strengthen national and regional readiness against a future ‘Disease X’. Discover more:

3 Sept

As global leaders gather for the UN General Assembly High-Level Meeting on Pandemic Prevention, Preparedness and Response, CEPI invites you to join its flagship side event: Building Crisis-Ready Coalitions: From Fragmentation to Readiness. Register now: web-eur.cvent.com/event/44c8f5...

3 Sept

The discussion will bring together leaders from government, industry, regulatory agencies and health organisations to explore how long-term partnerships can transform fragmented efforts into collective readiness for the 100 Days Mission.

linkedin.comClosing the mpox vaccine access gap for mothers and young childrenA new outbreak of mpox in Guinea-Bissau, the first recorded in the country, is a stark reminder that the virus remains a global threat. Mpox is not a new disease, but since the virus began spreading m...

1 Sept

CEPI's August newsletter is now available ⬇️ This edition spotlights CEPI’s ongoing efforts to close the mpox vaccine access gap, the latest progress in the fight against Bundibugyo ebolavirus—including funding for a fifth vaccine candidate and the initiation of another Phase 1 trial—and lots more.

27 Aug

We've announced a new US$16.5 million partnership with African biopharmaceutical company Minapharm Group to develop their Bundibugyo vaccine candidate. The Bundibugyo epidemic in the DRC is the fastest-growing and second-largest Ebola outbreak on record: cepi.net/african-bund...

cepi.net100 days into the Bundibugyo emergency, unprecedented speed is still not enoughThe first 100 days of the Bundibugyo outbreak show how far epidemic response has advanced and how far it still has to go. It's painful proof that in a deadly epidemic, even faster than ever is often n...

25 Aug

100 days into the Bundibugyo emergency, the global health response has moved at a pace unimaginable a decade ago. Yet the outbreak is far from contained. It's painful proof that in a deadly epidemic, even faster than ever is often not fast enough. ➡️ Read more on our website:

25 Aug

And in CEPI’s policy briefing document ‘100 days into the Bundibugyo response’: static.cepi.net/downloads/20...

cepi.netNew studies to test whether existing Ebola vaccines can generate immune responses to Bundibugyo ebolavirusCEPI-backed studies will analyse blood samples from thousands of people who have already been vaccinated against Zaire ebolavirus, with first results expected within months.

20 Aug

Do existing vaccines against Zaire ebolavirus generate immune responses to Bundibugyo ebolavirus?

Pandemic Center at Brown University’s School of Public Health

20 Aug

CEPI is investing US$4.17m in four research projects to help answer this pressing question. The projects will test whether existing Ebola vaccines, including Ervebo, can generate immune responses against Bundibugyo, the virus behind the outbreak in DRC. First results expected within months.

CEPI reposted

@pandemiccenter.bsky.social

17 Aug

A new report from @pandemiccenter.bsky.social, @cepi.net, and @rand.org details key areas for defense and health investment to advance #100DaysMission and outlines recommendations for cross-sector collaboration to deliver faster pandemic preparedness and response. static.cepi.net/downloads/20...

We’re delighted to announce that the CEPI Board has appointed Professor Ibrahim Abubakar as CEPI’s next Chief Executive Officer. cepi.net/cepi-board-a...

“Through its focus on innovation and equitable access, CEPI has made huge progress over the last decade”, said Professor Abubakar. “I believe there is an opportunity to build on that progress and make a transformational difference to how the world tackles epidemics and pandemics."

"I am truly honoured to be given the opportunity to take on this role and am looking forward to leading CEPI through its next chapter.” Please join us in welcoming Professor Ibrahim Abubakar to CEPI!

We’re delighted to announce that the CEPI Board has appointed Professor Ibrahim Abubakar as CEPI’s next Chief Executive Officer. cepi.net/cepi-board-a...

Professor Abubakar brings extensive leadership experience across global public health and international organisations.

He most recently served as Vice-Provost and Professor of Infectious Disease Epidemiology at UCL, overseeing the University’s health strategy and a portfolio of research, innovation and clinical partnerships.

We’re delighted to announce that the CEPI Board has appointed Professor Ibrahim Abubakar as CEPI’s next Chief Executive Officer. cepi.net/cepi-board-a...

"... to acting as an advisor to the Nigerian Presidential Taskforce through to his current role at UCL. He has a clear, personal commitment to the values that make CEPI unique: international collaboration and scientific excellence in service of equitable access for everyone, everywhere."

"The world cannot afford to be caught unprepared by the next pandemic, and under Ibrahim’s leadership I am confident CEPI will be ready.”

We’re delighted to announce that the CEPI Board has appointed Professor Ibrahim Abubakar as CEPI’s next Chief Executive Officer. cepi.net/cepi-board-a...

Dr Richard Hatchett, who has led CEPI since its founding in 2017, will remain as CEO until the end of his full term in April 2027, ensuring a smooth transition.

Welcoming Professor Abubakar to CEPI, Hon Prof Jane Halton, Chair of the CEPI Board, said: “Ibrahim’s appointment reflects an outstanding track record of delivery and achievement from leading the Lancet Nigeria Commission..."

We’re delighted to announce that the CEPI Board has appointed Professor Ibrahim Abubakar as CEPI’s next Chief Executive Officer. cepi.net/cepi-board-a...

Professor Abubakar, currently Vice-Provost (Health) and Professor of Infectious Disease Epidemiology at University College London (UCL), will take up the role in April 2027.

CEPI reposted

4 Aug

The first participant has been dosed in a CEPI-backed Phase 1 trial of Moderna's investigational vaccine against Bundibugyo virus, marking rapid progress in the global effort to combat the deadly Ebola outbreak in DRC. Read more: cepi.net/modernas-bun...

CEPI has committed up to US$50 million to advance Moderna’s vaccine candidate from preclinical testing through Phase 1 trials and scaled manufacturing of additional clinical trial doses so larger efficacy studies can launch rapidly if results are promising.

4 Aug

Under its agreement with CEPI, Moderna has committed to enabling rapid supply and access to its Bundibugyo vaccine to affected countries and to the populations that need it.

"Every day matters and every vaccine candidate in clinical trials gives us another shot at getting a safe, effective vaccine to the people who need it as swiftly as possible," said Dr Richard Hatchett, CEPI's CEO.